| Preliminary Program subject to change | |||||||||
| TI014 Particle Engineering in the Active Pharmaceutical Ingredient and Drug Product Manufacturing | |||||||||
| Overview | Physical properties of pharmaceutical particles are greatly affected by particle size distribution and morphology. In many occasions the particles need to be engineered to meet certain formulation and process requirements. This session highlights advances in particle engineering to address process and formulation issues in the pharmaceutical industry. Particle engineering techniques in both API synthesis and drug product formulation are welcome. Sample cases include production of small crystals to improve bioavailability or compactability, particle size enlargement or morphology modification to improve powder flowability and bulk density, and granulation to improve drug product formulation processes, etc. | ||||||||
| Primary Sponsor | Topical I: Pharmaceutical Engineering for the 21^st Century (TI) | ||||||||
| Co-Sponsor(s) | Pharmaceuticals (15b) | ||||||||
ChairBing-Shiou YangPrincipal Scientist Boehringer Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Rd./P.O. Box 368 Ridgefield, CT 06877-0368 Phone Number: 203-791-6883 Email: byang2@rdg.boehringer-ingelheim.com
CoChairPraveen K. SharmaResearch Investigator II Process Research & Development Bristol-Myers Squibb Co. 1 Squibb Drive New Brunswick, NJ 08903 Phone Number: 732-227-5186 Email: praveen.sharma@bms.com | |||||||||
| |||||||||